Zobrazeno 1 - 10
of 399
pro vyhledávání: '"Jane B Trepel"'
Autor:
Elena Giudice, Tzu-Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, Nahoko Sato, Jane B. Trepel, Jung-Min Lee
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-gr
Externí odkaz:
https://doaj.org/article/a32a2dc2018942d5a1dda8aa8f8851d8
Autor:
Thomas L Prince, Toshiki Kijima, Manabu Tatokoro, Sunmin Lee, Shinji Tsutsumi, Kendrick Yim, Candy Rivas, Sylvia Alarcon, Harvey Schwartz, Kofi Khamit-Kush, Bradley T Scroggins, Kristin Beebe, Jane B Trepel, Len Neckers
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0141786 (2015)
The two cytosolic/nuclear isoforms of the molecular chaperone HSP90, stress-inducible HSP90α and constitutively expressed HSP90β, fold, assemble and maintain the three-dimensional structure of numerous client proteins. Because many HSP90 clients ar
Externí odkaz:
https://doaj.org/article/0ff6f1ea8e0146d899d256ab4307650b
Autor:
Alessio Giubellino, Carole Sourbier, Min-Jung Lee, Brad Scroggins, Petra Bullova, Michael Landau, Weiwen Ying, Len Neckers, Jane B Trepel, Karel Pacak
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56083 (2013)
Metastatic pheochromocytoma represents one of the major clinical challenges in the field of neuroendocrine oncology. Recent molecular characterization of pheochromocytoma suggests new treatment options with targeted therapies. In this study we invest
Externí odkaz:
https://doaj.org/article/c48752536b4543e1a016f846ad0fb09b
Autor:
Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibod
Externí odkaz:
https://doaj.org/article/7b50e02d4e8d4d54b44bd8cfb4b2d620
Systemic immune changes accompany combination treatment with immunotoxin LMB ‐100 and nab‐paclitaxel
Autor:
Guillaume Joe Pegna, Min‐Jung Lee, Cody J. Peer, Mehwish I. Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine
Publikováno v:
Cancer Medicine. 12:4236-4249
LMB-100 is a novel immune-conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB-100 ± nab-paclitaxel. Participant blood samples were a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f266d94506f1f3f0da5b65b19da4697
https://doi.org/10.1002/cam4.5290
https://doi.org/10.1002/cam4.5290
Autor:
R. Taylor Ripley, David S. Schrump, Jonathan M. Hernandez, Chuong D. Hoang, Jeremy L. Davis, Leonard M. Neckers, Derek J. Nancarrow, David G. Beer, Laurence P. Diggs, Kaitlin C. McLoughlin, Sichuan Xi, Shaojian Gao, Min-Jung Lee, Sunmin Lee, Jane B. Trepel, Daniel R. Crooks, Emily S. Reardon, Vivek Shukla, Lucas A. McDuffie, Yuan Xu, Kate Brown, Deborah R. Surman, Paul L. Feingold
RNAse Esc2 TXNIP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59cb2352cf6ee8517ba836977219d285
https://doi.org/10.1158/1535-7163.22505272.v1
https://doi.org/10.1158/1535-7163.22505272.v1
Autor:
R. Taylor Ripley, David S. Schrump, Jonathan M. Hernandez, Chuong D. Hoang, Jeremy L. Davis, Leonard M. Neckers, Derek J. Nancarrow, David G. Beer, Laurence P. Diggs, Kaitlin C. McLoughlin, Sichuan Xi, Shaojian Gao, Min-Jung Lee, Sunmin Lee, Jane B. Trepel, Daniel R. Crooks, Emily S. Reardon, Vivek Shukla, Lucas A. McDuffie, Yuan Xu, Kate Brown, Deborah R. Surman, Paul L. Feingold
In 2017, an estimated 17,000 individuals were diagnosed with esophageal adenocarcinoma (EAC), and less than 20% will survive 5 years. Positron emission tomography avidity is indicative of high glucose utilization and is nearly universal in EAC. TXNIP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e340b99ca40389ffa9f98c0fced22dc
https://doi.org/10.1158/1535-7163.c.6538015.v1
https://doi.org/10.1158/1535-7163.c.6538015.v1
Autor:
R. Taylor Ripley, David S. Schrump, Jonathan M. Hernandez, Chuong D. Hoang, Jeremy L. Davis, Leonard M. Neckers, Derek J. Nancarrow, David G. Beer, Laurence P. Diggs, Kaitlin C. McLoughlin, Sichuan Xi, Shaojian Gao, Min-Jung Lee, Sunmin Lee, Jane B. Trepel, Daniel R. Crooks, Emily S. Reardon, Vivek Shukla, Lucas A. McDuffie, Yuan Xu, Kate Brown, Deborah R. Surman, Paul L. Feingold
Cells and Reagents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bce5e7960c6cb1e98e4c8f87eeb3406
https://doi.org/10.1158/1535-7163.22505263
https://doi.org/10.1158/1535-7163.22505263
Autor:
R. Taylor Ripley, David S. Schrump, Jonathan M. Hernandez, Chuong D. Hoang, Jeremy L. Davis, Leonard M. Neckers, Derek J. Nancarrow, David G. Beer, Laurence P. Diggs, Kaitlin C. McLoughlin, Sichuan Xi, Shaojian Gao, Min-Jung Lee, Sunmin Lee, Jane B. Trepel, Daniel R. Crooks, Emily S. Reardon, Vivek Shukla, Lucas A. McDuffie, Yuan Xu, Kate Brown, Deborah R. Surman, Paul L. Feingold
Supplemental Figure 1: Chromatin immunoprecipitation was performed to assess the histone modification marks, H3K27Me3, H3K9Ac2, H3K4Me3, and H3K79Me2 in Flo-1 and Esc2 after glutamine withdrawal; Supplemental Figure 2: qRT-PCR normalized to b-actin m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddae6a9e59936bf7cb288418158c173
https://doi.org/10.1158/1535-7163.22505275
https://doi.org/10.1158/1535-7163.22505275
Autor:
Jane B. Trepel, Len Neckers
Inhibitors of the molecular chaperone HSP90 have been in clinical development as anticancer agents since 1999. Recent clinical studies, including the work of Saif and colleagues in this issue of Clinical Cancer Research, demonstrate that significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22424d8292022945ebafbcfdb2a81aa6
https://doi.org/10.1158/1078-0432.c.6521301
https://doi.org/10.1158/1078-0432.c.6521301